Antiviral Drugs for Arenaviruses

沙粒病毒的抗病毒药物

基本信息

批准号：
8076702
负责人：
SEAN M AMBERG
金额：
$ 177.92万
依托单位：
SIGA TECHNOLOGIES, INC.
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-08-17 至 2016-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8076702
关键词：
Animal Model Animals Antiviral Agents Arenavirus Binding Biological Biological Availability Categories Cavia Chemicals Chemistry Clinical Data Development Dose Drug Interactions Drug Kinetics Drug resistance Evaluation Foundations Genetic Genetic Determinism Glycoproteins Goals Human In Vitro Investigational New Drug Application Junin virus Lassa Fever Lassa virus Lead Libraries Macaca fascicularis Metabolism Modeling Monitor Mutation Organ Pharmaceutical Chemistry Pharmaceutical Preparations Pharmacology Pharmacology and Toxicology Predisposition Preparation Proteins Reporting Resistance Ribavirin Safety Screening procedure Series Solubility Specificity Structure Structure-Activity Relationship Tacaribe Complex Viruses Testing Toxic effect Toxicology Variant Viral Viral Hemorrhagic Fevers Virus analog analytical method animal efficacy base chemical synthesis cost effective drug metabolism drug resistant virus efficacy evaluation fitness genotoxicity hemorrhagic fever virus in vivo inhibitor/antagonist large scale production nonhuman primate pharmacophore pre-clinical prevent programs protective efficacy small molecule

项目摘要

DESCRIPTION (provided by applicant): The goal of the program described here is to develop an antiviral drug for treating and preventing Lassa fever and other hemorrhagic fevers of arenavirus origin. Previous library screening identified several good candidate small molecule inhibitors of Lassa virus entry. Subsequent in vitro and in vivo characterization identified a potent series, ST-193, with broad- spectrum activity against 5 distinct Category A hemorrhagic fever Arenaviruses. This series has shown protective efficacy in two animal models of Lassa fever, guinea pigs and cynomolgus monkeys. The specific objective of this application is to optimize this chemical series to identify an appropriate candidate for preclinical development and to collect the necessary data to support the submission of an application for an Investigational New Drug (IND).

描述（由申请人提供）：此处描述的程序的目的是开发一种抗病毒药，用于治疗和预防甲状腺病毒起源的LASSA热和其他出血性发烧。先前的库筛选确定了LASSA病毒进入的几个好的小分子抑制剂。随后的体外和体内表征确定了有效的ST-193序列，具有针对5种不同类别A出血热的竞技病毒的广谱活性。该系列显示了两种lassa热，豚鼠和cynomolgus猴子的动物模型中的保护作用。本应用的具体目标是优化该化学系列，以确定临床前开发的适当候选者，并收集必要的数据，以支持提交研究性新药的应用程序（IND）。